OT-551(OT-551) - 药物靶点：SOD1_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

SOD1

作用方式

刺激剂

作用机制

SOD1刺激剂(超氧化物歧化酶刺激剂)

治疗领域

神经系统疾病遗传病与畸形内分泌与代谢疾病+ [2]

在研适应症-

非在研适应症

白内障干性年龄相关性黄斑病变干眼综合征+ [7]

原研机构

Colby Pharmaceutical Co.

在研机构-

非在研机构

Othera Pharmaceuticals, Inc.

Colby Pharmaceutical Co.Colby

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C13H23NO3

InChIKeyZWEXEKJLDHNLLA-UHFFFAOYSA-N

CAS号627085-11-4

查看全部结构式(2)

关联

3

项与 OT-551 相关的临床试验

NCT00485394

/ Unknown status临床2期

A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II Study Comparing the Safety and Efficacy of OT-551 With Placebo to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration

The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.

开始日期2007-06-01

申办/合作机构

Othera Pharmaceuticals, Inc.

NCT00306488

/ Completed临床2期IIT

A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration

Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration. This pilot study of up to 10 eye drop tolerant participants with bilateral geographic atrophy is designed to characterize the effect of 0.45% concentration of OT-551 eye drops given 3 times a day on the progression of geographic atrophy area over a two-year period. Participants will have one eye randomized to receive the eye drop and the fellow eye will be observed only.

开始日期2006-03-01

申办/合作机构

National Institutes of Health Clinical Center

[+2]

NCT00333060

/ Terminated临床2期

Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients

The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively prevent or delay the progression of nuclear cataracts that frequently develop as a result of vitrectomy (surgery for retina repair), thereby avoiding the need for a second surgery (cataract removal). Victrectomies involve removal of the jelly-like substance (vitreous) that is located in a cavity behind the lens.

开始日期2005-11-01

申办/合作机构

Othera Pharmaceuticals, Inc.

100 项与 OT-551 相关的临床结果

登录后查看更多信息

100 项与 OT-551 相关的转化医学

登录后查看更多信息

100 项与 OT-551 相关的专利（医药）

登录后查看更多信息

7

项与 OT-551 相关的文献（医药）

2013-09-01·Expert Review of Clinical Pharmacology2区 · 医学

Update on current and future novel therapies for dry age-related macular degeneration

2区 · 医学

Review

作者: Ella Leung ; Gennady Landa

Age-related macular degeneration (ARMD) is the leading cause of irreversible blindness in developed countries. There are currently no cures, but there are promising potential therapies that target the underlying disease mechanisms of dry ARMD. Stem cells, ciliary neurotrophic factor, rheopheresis, ozonated autohemotherapy and prostaglandins show promise in stabilizing or improving visual acuity. Age-Related Eye Disease Study vitamins may reduce progression to severe ARMD. Adjuvant therapy like low vision rehabilitation and implantable miniature telescopes may help patients adjust to the sequelae of their disease, and herbal supplementation with saffron, zinc monocysteine and phototrop may be helpful. Therapies that are currently in clinical trials include brimonidine, doxycycline, anti-amyloid antibodies (GSK933776 and RN6G), RPE65 inhibitor (ACU-4429), complement inhibitors (ARC1905, FCFD4514S), hydroxychloroquine, intravitreal fluocinolone acetate and vasodilators like sildenafil, moxaverine and MC-1101. Therapies that have not been shown to be effective include POT-4, eculizumab, tandospirone, anecortave acetate, the antioxidant OT-551, sirolimus and vitamin E.

2010-12-01·Investigative Opthalmology & Visual Science2区 · 医学

Treatment of Geographic Atrophy by the Topical Administration of OT-551: Results of a Phase II Clinical Trial

2区 · 医学

ArticleOA

作者: Meyerle, Catherine B. ; Harrington, Molly ; Ferris, Frederick L. ; Sadda, Srinivas R. ; Cunningham, Denise ; Hammel, Keri ; Chew, Emily Y. ; Wong, Wai T. ; Cukras, Catherine ; Kam, Waynekid

PURPOSETo investigate the safety and preliminary efficacy of OT-551, a disubstituted hydroxylamine with antioxidant properties, for the treatment of geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration (AMD).METHODSThe study was a single-center, open-label phase II trial, enrolling 10 participants with bilateral GA. Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years. Safety measures were assessed by complete ophthalmic examination, fundus photography, and review of symptoms. The primary efficacy outcome measure was the change in best corrected visual acuity at 24 months. Secondary efficacy measures included changes in area of GA, contrast sensitivity, microperimetry measurements, and total drusen area from baseline.RESULTSStudy drug was well tolerated and was associated with few adverse events. The mean change in BCVA at 2 years was +0.2 ± 13.3 letters in the study eyes and -11.3 ± 7.6 letters in fellow eyes (P = 0.0259). However, no statistically significant differences were found between the study and fellow eyes for all other secondary outcome measures.CONCLUSIONSOT-551 was well tolerated by study participants and was not associated with any serious adverse effects. Efficacy measurements in this small study indicate a possible effect in maintaining visual acuity. However, the absence of significant effects on other outcomes measures in this study suggests that OT-551, in the current concentration and mode of delivery, may have limited or no benefit as a treatment for GA (ClinicalTrials.gov number, NCT00306488).

2010-07-01·Experimental Eye Research3区 · 医学

Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats

3区 · 医学

Article

作者: Masaki Tanito ; Robert E. Anderson ; Feng Li

OT-551 (1-hydroxy-4-cyclopropanecarbonyloxy-2,2,6,6-tetramethylpiperidine hydrochloride), is a novel small molecule with antioxidant and anti-inflammatory effects. Protective efficacy of OT-551 and its metabolite TEMPOL-H (TP-H) against light-induced degeneration of retinal pigment epithelium (RPE) was tested. Albino rats were intraperitoneally injected with OT-551, TP-H, or water approximately 30 min prior to a 6 h exposure to 2700 lux white fluorescent light. Retinal protection was evaluated histologically by counting the RPE cell nuclei and measuring the extent of RPE damage on the retinal sections as RPE damage index (%). Following light exposure, the number of RPE cell nuclei was significantly reduced in light-exposed eyes from water-treated animals, while the number was not significantly different between light-exposed and unexposed eyes from the animals treated with 100 mg/kg TP-H or with any dose of OT-551 in the inferior hemisphere, and with 100 mg/kg OT-551 in the superior hemisphere. RPE damage index was significantly lower in the animals treated with any dose of OT-551 compared to water-treated animals both in the inferior and superior hemispheres. Systemic administration of OT-551 and TP-H provides RPE cell protection against acute light damage, and the protection by OT-551 was greater than by TP-H.

100 项与 OT-551 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05650

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
白内障	临床2期	美国	Colby	2012-12-11
青光眼	临床2期	美国	Colby Pharmaceutical Co.	2012-09-19
泪腺疾病	临床2期	美国	Colby Pharmaceutical Co.	2012-09-19
干性年龄相关性黄斑病变	临床2期	美国	Othera Pharmaceuticals, Inc.	2007-06-01
地图样萎缩	临床2期	美国	Othera Pharmaceuticals, Inc.	2006-03-01
II型糖原贮积病	临床2期	美国	Othera Pharmaceuticals, Inc.	2006-03-01
视网膜前膜	临床2期	美国	Othera Pharmaceuticals, Inc.	2005-11-01
核性白内障	临床2期	美国	Othera Pharmaceuticals, Inc.	2005-11-01
视网膜穿孔	临床2期	美国	Othera Pharmaceuticals, Inc.	2005-11-01
干眼综合征	临床2期	美国	Othera Pharmaceuticals, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00306488 (Pubmed \| Invest Ophthalmol Vis Sci)	临床2期	地图样萎缩	10	OT-551 0.45%	(築壓遞鹹繭遞積築衊窪) = 網壓鏇遞壓鏇餘製鬱膚積繭鑰遞襯夢簾顧淵獵 (夢醖鑰衊蓋觸襯窪膚築 )	不佳	2010-12-01
NCT00485394 (ARVO2010)	临床2期	地图样萎缩	137	OT-551 0.3%	(鑰遞製憲積糧醖餘築齋) = 築艱夢夢願鏇蓋膚窪餘醖範築齋鑰蓋鏇簾築糧 (獵壓積範醖網鏇積蓋壓 ) 更多	不佳	2010-04-01
NCT00485394 (ARVO2010)	临床2期	地图样萎缩	137	OT-551 0.45%	(鑰遞製憲積糧醖餘築齋) = 鹽衊鏇顧築膚網憲構積醖範築齋鑰蓋鏇簾築糧 (獵壓積範醖網鏇積蓋壓 ) 更多	不佳	2010-04-01
NCT00306488 (Phase I/II Clinical Trial, ARVO2010)	临床1/2期	地图样萎缩	10	OT-551 0.45%	(衊夢餘築築鑰繭構製鏇) = 顧繭積鹹鑰鹹積夢範夢鏇觸觸選構築膚醖遞網 (顧觸構鹹範構廠範餘願 )	积极	2010-04-01